In this study, 46 Algerian patients with MHC class II deficiency are characterized, revealing an early-onset disorder with substantial clinical and immunologic heterogeneity. The RFXANK c.338-25_338del26 founder variant remains predominant, while additional RFXANK, RFXAP, and CIITA variants expand the molecular spectrum.
Abstract
MHC class II deficiency is the most frequent combined immunodeficiency (CID) in the Maghreb, yet its phenotypic and molecular spectrum remains incompletely defined. Herein, we characterized 46 Algerian patients at the clinical, immunologic, and molecular levels. Disease onset was typically early, with a median age of 4.5 mo, while the clinical course was highly heterogeneous, ranging from severe, rapidly progressive disease to milder phenotypes with survival into adulthood. Recurrent infections were a universal feature, with protracted diarrhea (80.4%), recurrent pneumonia (71.7%), and oral candidiasis (54.3%) being the most common manifestations. CD4 lymphopenia occurred in 87% of patients, although lymphocyte profiles ranged from near-normal to SCID-like. Absent or nearly absent HLA-DR expression on both B cells and monocytes was observed in 44 patients, while two exhibited residual HLA-DR expression on B cells. Among 35 genetically characterized patients, 30 (85.7%) carried the recurrent RFXANK c.338-25_338del26 founder variant, while additional variants in RFXANK, RFXAP, and CIITA further broadened the molecular spectrum.
Introduction
MHC class II deficiency is a rare autosomal recessive combined immunodeficiency (OMIM #209920), first described in the late 1970s (1). The disorder is characterized by absent or profoundly reduced expression of MHC class II molecules on antigen-presenting cells, leading to severe impairment of CD4+ T cell development and function. Early investigations demonstrated that the MHC locus remains structurally intact in affected individuals, whereas MHC class II transcripts are absent, thereby establishing the disorder as a defect of transcriptional regulation rather than of gene structure itself (2, 3). Subsequent somatic cell fusion studies identified four distinct complementation groups (A–D) (4), each caused by mutations in one of four key transcriptional regulators required for MHC class II expression: CIITA (group A) (5), RFXANK (group B) (6), RFX5 (group C) (7), and RFXAP (group D) (8). RFXANK, RFX5, and RFXAP encode the components of the RFX complex, a DNA-binding multiprotein complex that recognizes conserved promoter elements of MHC class II genes and cooperates with additional transcription factors to assemble the MHC class II enhanceosome. CIITA acts as the master transactivator of this machinery, coordinating transcriptional activation of MHC class II genes. Defects in any of these regulatory factors abolish or severely impair MHC class II expression, giving rise to the profound combined immunodeficiency known as MHC class II deficiency, also referred to as bare lymphocyte syndrome type II (9).
The absence of MHC class II expression disrupts the development and function of CD4+ T cells, impairing both cellular and humoral immune responses. Affected patients typically exhibit hypogammaglobulinemia and markedly reduced CD4+ T cell counts, while CD8+ T cells are relatively preserved (10, 11). Clinically, they present with early-onset, severe, and/or recurrent infections predominantly affecting the respiratory and gastrointestinal tracts, often accompanied by protracted diarrhea and failure to thrive (10, 11, 12, 13). Although most patients become symptomatic within the first year of life, some may experience delayed diagnosis due to a milder disease course, with clinical onset occasionally extending into adolescence (12, 14).
MHC class II deficiency exhibits a remarkable geographic concentration among individuals of Maghrebi ancestry, particularly from Algeria, Morocco, and Tunisia, where most reported cases originate. This predominance is primarily explained by a founder mutation in the RFXANK gene, a 26-base pair deletion (c.338-25_338del26, also known as 752delG-25), identified in 73.5–97.1% of affected Maghrebi patients, including many without documented consanguinity (11, 12, 13). In Algeria, data from the Algerian Registry for Inborn Errors of Immunity in Children highlight MHC class II deficiency as a major contributor to the burden of combined immunodeficiencies (CIDs), representing more than 30% of all CIDs (including severe CIDs [SCIDs]) and over half of bona fide CID cases (15). Despite its unusually high prevalence in Algeria, MHC class II deficiency has been described in only a small cohort of 11 patients, primarily focused on the identification of the c.338-25_338del26 founder variant, leaving its broader phenotypic and genetic spectrum incompletely defined (11). Hence, we report a large Algerian cohort of 46 patients comprehensively characterized at the clinical, immunologic, and genetic levels. Our findings highlight an early-onset disorder with substantial clinical and immunologic heterogeneity and further expand its molecular spectrum beyond the prevalent founder variant to include RFXAP and CIITA defects, identified for the first time in Algerian patients. Collectively, these data provide a more comprehensive characterization of MHC class II deficiency and may facilitate earlier recognition and more precise diagnosis, particularly in endemic settings.
Results
Demographic data and clinical characteristics
We investigated 46 patients (32 males and 14 females) from 42 unrelated families. Parental consanguinity was documented in 31 patients (67.4%). The median age at last follow-up or death was 60 mo (interquartile range [IQR], 27–96), with extremes ranging from 7 mo to 19 years. The median age at diagnosis was 17.5 mo (IQR, 8–37.5), with a range from 1 to 108 mo. Symptom onset occurred at a median age of 4.5 mo (2–9.7), and the median diagnostic delay was 11 mo (5–23) (Fig. 1 A). Three patients, i.e., P19, P23, and P26, were diagnosed through family screening before the onset of significant clinical manifestations. As summarized in Table 1, recurrent infections were a universal feature of this cohort, predominantly involving the respiratory and gastrointestinal tracts. Protracted diarrhea was the most frequent manifestation, occurring in 37 of 46 patients (80.4%), followed by recurrent pneumonia in 33 (71.7%) and upper respiratory tract infections in 20 (43.5%). Recurrent or persistent oral candidiasis was reported in 25 patients (54.3%), with esophageal involvement in 9 (19.6%). Skin infections were less frequent, occurring in 16 patients (34.8%), and included bacterial abscesses as well as viral and fungal infections. Documented viral infections occurred in 10 patients (21.7%), including molluscum contagiosum in three and severe varicella in two. Respiratory viral infections occurred in three patients, while viral gastroenteritis and CMV hepatitis were each reported in one (Fig. 1 B).
Figure 1.

Demographic, clinical, and immunological characteristics of patients with MHC class II deficiency. (A) Violin plots showing patients’ age at symptom onset, age at diagnosis, and age at last documented follow-up. (B) Overview of the main clinical features of the cohort. (C) Initial clinical presentation of patients with MHC class II deficiency. (D) Bar plots showing the frequency of patients with low, normal, or high serum immunoglobulin levels and T, B, and NK cell subset counts. Serum immunoglobulin levels were measured in 45 patients; T, B, and NK cell enumeration was performed in all patients, extended T cell subset phenotyping in 29, and B cell subset analysis in 14 patients. ENT, ear, nose, and throat.
Table 1.
Demographic data and clinical characteristics of patients with MHC class II deficiency
| Family | Patient | Sex | Genea | Consanguinity | Family history | Age (mo)b | Age at onset (mo) | Age at diagnosis (mo) | Persistent diarrhea | Pneumonia | Isolated pathogens | Failure to thrive | Autoimmunity | Allergy | Status | HSCT | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | P1 | F | RFXANK | + | − | 36 | 4 | 11 | + | + | P. aeruginosa Cryptosporidium spp. | + | − | − | Dead | − | Pneumonia, ARDS |
| 2 | P2 | M | RFXANK | − | + | 84 | 5 | 60 | + | − |
P. aeruginosa
S. aureus |
+ | − | − | Dead | − | Septic shock |
| 3 | P3 | F | RFXANK | + | + | 36 | 2 | 8 | + | + | − | − | − | Asthma | Dead | − | NA |
| 4 | P4 | M | RFXANK | + | − | 96 | 2 | 48 | + | + | S. aureus | + | − | − | Dead | − | NA |
| 5 | P5 | F | RFXANK | + | + | 72 | 7 | 22 | + | + | P. aeruginosa | + | − | − | Dead | − | NA |
| 6 | P6 | M | RFXANK | + | − | 60 | 4 | 27 | + | + | M. pneumoniae | + | − | Asthma | Dead | − | Pneumonia, ARDS |
| 7 | P7 | M | RFXANK | − | − | 70 | 4 | 22 | + | + |
S. aureus
P. aeruginosa S. pyogenes H. influenzae K. pneumoniae S. typhi |
+ | − | − | Dead | − | Pneumonia, sepsis |
| 8 | P8 | F | RFXANK | + | − | 60 | 8 | 48 | + | + | − | + | − | − | Dead | − | Severe malnutrition, sepsis |
| 9 | P9 | M | RFXANK | − | − | 232 | 3 | 76 | − | + |
S. pneumoniae
S. aureus |
+ | − | − | Alive | − | |
| 10 | P10 | M | RFXANK | − | − | 216 | 7 | 60 | − | + | E. coli | − | − | − | Alive | − | |
| 11 | P11 | M | ND | + | − | 18 | 1 | 4 | + | + | − | + | − | − | Dead | − | Sepsis |
| 12 | P12 | M | RFXANK c | + | + | 40 | 6 | 16 | + | + | S. pneumoniae | + | − | − | Dead | − | NA |
| 13 | P13 | F | ND | + | − | 24 | 4 | 8 | + | + | − | + | − | Eczema | Dead | − | NA |
| 14 | P14 | M | ND | − | − | 30 | 3 | 10 | − | + | − | + | − | − | Dead | − | Pneumonia, ARDS |
| 15 | P15 | M | ND | + | + | 18 | 5 | 9 | + | + | H. influenzae | + | − | − | Dead | − | NA |
| 16 | P16 | F | ND | + | + | 32 | 2 | 7 | + | + | − | + | − | − | Dead | − | NA |
| 17 | P17 | M | ND | − | − | 27 | 8 | 12 | + | + | − | + | − | − | Dead | − | NA |
| 18 | P18 | F | ND | + | − | 18 | 4 | 6 | + | − | − | + | − | − | Dead | − | NA |
| 19 | P19 | F | ND | + | + | 24 | 4 | 1 | + | + | − | + | − | − | Dead | − | Severe malnutrition, sepsis |
| 20 | P20 | M | ND | + | + | 36 | 18 | 18 | + | − | − | + | − | − | Dead | − | Severe malnutrition, sepsis |
| 21 | P21 | M | RFXANK | − | + | 122 | 12 | 33 | + | − | − | + | − | Asthma | Alive | + | |
| 22 | P22 | M | RFXANK | − | + | 84 | 6 | 17 | + | − | Leishmania infantum | + | − | − | Alive | − | |
| 22 | P23 | F | RFXANK | − | + | 78 | 2 | 1 | + | + | Aspergillus spp. | + | − | − | Alive | + | |
| 23 | P24 | M | ND | + | + | 60 | 1 | 8 | + | − | − | + | − | − | Dead | − | Severe malnutrition, sepsis |
| 24 | P25 | M | RFXANK | + | − | 96 | 16 | 24 | + | − | Cryptosporidium spp. | + | − | − | Dead | − | Severe malnutrition |
| 24 | P26 | F | RFXANK | − | + | 64 | 12 | 6 | + | − | − | − | − | − | Dead | − | NA |
| 25 | P27 | M | RFXANK | + | + | 216 | 3 | 18 | − | + | P. aeruginosa | + | AIHA | − | Alive | − | |
| 26 | P28 | M | RFXANK | + | − | 132 | 14 | 24 | + | − | − | − | − | − | Alive | − | |
| 27 | P29 | M | RFXANK | − | − | 132 | 1 | 24 | + | − |
H. influenzae
Cryptosporidium spp. |
+ | − | − | Alive | + | |
| 28 | P30 | F | RFXANK | + | − | 110 | 18 | 48 | + | + | Staphylococcus aureus | + | Arthritis | − | Alive | + | |
| 29 | P31 | M | RFXANK | + | + | 96 | 60 | 96 | + | − | − | − | − | − | Alive | − | |
| 30 | P32 | M | CIITA | + | + | 9 | 3 | 8 | − | + | − | + | − | − | Dead | − | Pneumonia, ARDS |
| 30 | P33 | M | CIITA | + | + | 7 | 1 | 7 | + | + | − | + | − | − | Dead | − | Pneumonia, ARDS |
| 31 | P34 | F | RFXANK | + | + | 132 | 6 | 96 | − | + | − | + | APS (Budd–Chiari Sd.) | − | Alive | − | |
| 32 | P35 | F | RFXAP | − | + | 16 | 3 | 9 | + | + | − | + | − | − | Dead | − | Septic shock |
| 33 | P36 | M | RFXANK | − | − | 60 | 18 | 36 | + | − | − | + | − | − | Alive | − | |
| 34 | P37 | M | RFXANK | + | − | 27 | 1 | 15 | + | + | − | − | − | − | Alive | − | |
| 35 | P38 | M | RFXANK | − | + | 32 | 6 | 20 | + | + | − | + | Autoimmune encephalitis | − | Dead | − | Autoimmune encephalitis |
| 36 | P39 | M | RFXANK | + | − | 42 | 9 | 22 | + | + | H. influenzae | + | − | Rhinitis | Dead | − | NA |
| 37 | P40 | M | RFXANK | + | + | 15 | 5 | 10 | + | − | − | + | − | − | Alive | − | |
| 38 | P41 | M | RFXANK | + | + | 22 | 1 | 12 | − | + | E. coli | − | − | − | Alive | − | |
| 39 | P42 | M | ND | − | − | 70 | 12 | 60 | − | + |
M. tuberculosis
S. aureus |
− | − | − | Alive | − | |
| 40 | P43 | M | RFXANK | + | + | 168 | 24 | 108 | + | + | H. influenzae | + | AIHA | CMPA | Alive | − | |
| 40 | P44 | M | RFXANK | + | + | 66 | 24 | 42 | − | + | − | + | − | − | Alive | − | |
| 41 | P45 | M | RFXAP | + | + | 14 | 1 | 4 | + | + | − | + | − | − | Dead | − | Meningoencephalitis |
| 42 | P46 | F | RFXANK | + | − | 72 | 2 | 13 | + | − |
P. aeruginosa
Enterobacter sp. G. duodenalis |
+ | AIHA | − | Alive | − | |
Bold values indicate genes/variants that differ from the founder RFXANK variant. ARDS, acute respiratory distress syndrome; CMPA, cow’s milk protein allergy; NA, not available; ND, not determined.
Genetic testing by WES was performed in 35 patients, with identification of a causative gene in all 35. The remaining 11 patients were not genetically tested.
The “Age” column indicates age at death for deceased patients and age at last documented follow-up for surviving patients.
A different RFXANK variant (c.673insC).
Microbiological investigations identified a range of bacterial, parasitic, and fungal pathogens, with Staphylococcus aureus and Pseudomonas aeruginosa being the most frequently isolated. Each was identified in six patients (S. aureus: P2, P4, P7, P9, P30, and P42; P. aeruginosa: P1, P2, P5, P7, P27, and P46). Hemophilus influenzae was identified in five patients (P7, P15, P29, P39, and P43). Other bacterial pathogens included Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Salmonella Typhi, Streptococcus pyogenes, Mycoplasma pneumoniae, and Mycobacterium tuberculosis. Parasitic pathogens included Cryptosporidium spp., detected in three patients (P1, P25, and P29) with persistent diarrhea, as well as Giardia duodenalis and Leishmania infantum, whereas fungal pathogens included Candida spp. and Aspergillus spp. (Table 1).
Failure to thrive was almost universal, affecting 37 patients (80.4%), likely reflecting the cumulative impact of recurrent infections, protracted diarrhea, and nutritional impairment. Autoimmune manifestations were documented in six patients (13.0%), including autoimmune hemolytic anemia (AIHA) in three (6.5%), and antiphospholipid syndrome, arthritis, and autoimmune encephalitis in one patient each (Table 1). Allergic manifestations were documented in six patients (13.0%), including asthma in three patients and cow’s milk protein allergy, allergic rhinitis, and eczema in one patient each. With respect to the initial clinical presentation, persistent diarrhea was the most common presenting feature, occurring in 19 patients (41.3%), followed by pneumonia in 15 (32.6%) (Fig 1 C).
Immunological profile
The immunophenotypic characterization of lymphocyte subsets is summarized in Table S1. Of the 46 patients, 26 (56.5%) had lymphopenia, 17 (37.0%) had normal lymphocyte counts, and 3 (6.5%) had lymphocytosis. T cell lymphopenia was observed in 21 patients (45.7%). An inverted CD4/CD8 ratio was observed in 35 patients (76.1%), largely reflecting the marked depletion of CD4+ T cells, which occurred in 40 patients (87.0%), whereas 6 (13.0%) had normal CD4+ T cell counts. CD8+ T cell counts were decreased in 14 patients (30.4%), normal in 20 (43.5%), and increased in 12 (26.1%). Extended T cell immunophenotyping, available for 29 patients, further delineated a marked contraction of naive T cell compartments. Naive CD4+ T cells were profoundly reduced in 27 of 29 patients (93.1%), whereas naive CD8+ T cells were decreased in 23 of 29 (79.3%). B cell lymphopenia was observed in 19 of 46 patients (41.3%). Among the 14 patients evaluated for B cell maturation subsets, switched memory B cells were reduced in 8 (57.1%), while CD21lo B cells were expanded in 3 (21.4%). Natural killer (NK) cell lymphopenia was identified in 9 of 46 patients (19.6%). Serum IgG levels were reduced in 20 of 45 tested patients (44.4%), whereas IgA and IgM levels were decreased in 32 (71.1%) and 19 (42.2%), respectively (Fig. 1 D and Fig. 2).
Figure 2.

Serum immunoglobulin levels and T, B, and NK cell subset counts in patients with MHC class II deficiency. Grey-blue shaded areas indicate age-matched normal ranges, with values outside considered abnormal (16, 17). Serum immunoglobulin levels were measured in 45 patients, T, B, and NK cell enumeration in all patients, and extended T cell subset phenotyping in 29 patients.
HLA-DR expression analysis
HLA-DR surface expression was absent or nearly absent (≤2%) on both B cells and monocytes in 44 patients, whereas two patients (P27 and P42) exhibited residual expression (Table S1). In P27, HLA-DR expression on B cells was highly variable between assessments. During hospitalization for severe pneumonia, 98% of B cells were HLA-DR positive, with a median florescence intensity (MFI) ∼30-fold lower than that of the control. On repeat assessment during hospitalization for AIHA, only 10% of B cells were HLA-DR positive, with an MFI ∼450-fold lower than the control. In contrast, HLA-DR expression on monocytes remained profoundly reduced at both assessments. In P42, the proportion of HLA-DR–positive B cells remained relatively stable at ∼90%, with less pronounced fluctuations over time. Nevertheless, HLA-DR expression intensity was markedly reduced, with an MFI 10- to 20-fold lower than that of the healthy control. By contrast, HLA-DR expression on monocytes remained nearly absent across repeated assessments (Fig. 3 A and Table S2).
Figure 3.

HLA-DR expression on monocytes and B cells and clinical outcomes in patients with MHC class II deficiency. (A) Flow cytometric analysis revealed two distinct patterns of HLA-DR expression. The top left panel shows representative dot plots demonstrating complete absence of HLA-DR expression on both monocytes and B cells in patient P33. The top right panel shows histograms illustrating fluctuating residual HLA-DR expression on B cells in patient P27. At the first assessment, 98% of B cells were HLA-DR positive, although their MFI was ∼30-fold lower than that of the healthy control. At the second assessment, only 10% of B cells were HLA-DR positive, with an MFI ∼450-fold lower than that of the control. (B) Patient distribution according to vital status at the last documented follow-up (bottom left) and Kaplan–Meier overall survival curve (bottom right). 1st D, first determination; 2nd D, second determination; HC, healthy control; IC, isotypic control; MFI, median florescence intensity.
Genetic findings
30 of the 35 tested patients (85.7%) harbored the recurrent homozygous RFXANK c.338-25_338del26 variant, consistent with its established founder effect in Maghrebi populations (10). The molecular consequences of this variant were previously defined by Nekrep et al., who showed that the 26-nucleotide deletion disrupts RFXANK splicing, resulting in loss of exons 5 and 6 from the mature transcript and a frameshift that preserves the first 90 aa’s but generates a truncated 124-residue protein. The resulting protein cannot bind RFXAP, thereby impairing RFX complex assembly and MHC class II transcription (18). Patient P12 harbored a homozygous c.673insC insertion in the same gene, leading to a frameshift starting at codon 227 and introducing a premature stop codon 32 aa’s downstream (p.Met227AspfsTer32). Two patients from unrelated kindreds, P35 and P45, harbored the same previously reported pathogenic RFXAP c.368del variant (p.Ser123ThrfsTer15), a frameshift deletion resulting in premature termination 15 aa’s downstream (8, 19) (Table 2).
Table 2.
Characteristics of pathogenic variants identified in 35 patients with MHC class II deficiency
| Patients | Gene | Nucleotide change (HGVS) | Protein change | Variant type | Zygosity | Molecular consequence |
|---|---|---|---|---|---|---|
| 30 patients | RFXANK | c.338-25_338del26 | – | Intronic deletion affecting splicing | Homozygous | Aberrant splicing with skipping of exons 5 and 6, resulting in a frameshift and a truncated 124-aa protein (18) |
| P12 | RFXANK | c.673insC | p.(Met227AspfsTer32) | Frameshift insertion | Homozygous | Frameshift beginning at codon 227, introducing a premature termination codon 32 aa’s downstream |
| P35, P45 | RFXAP | c.368del | p.(Ser123ThrfsTer15) | Frameshift deletion | Homozygous | Frameshift beginning at codon 123, introducing a premature termination codon 15 aa’s downstream (8, 19) |
| P32, P33 | CIITA | c.3233+1G>A | – | Canonical splice-donor variant | Homozygous | Predicted disruption of the canonical donor splice site, potentially resulting in in-frame exon 17 skipping (SpliceAI DS-DL = 0.98; Pangolin = 0.84) |
HGVS, Human Genome Variation Society.
A novel homozygous CIITA c.3233+1G>A variant was identified in two siblings, P32 and P33, at the canonical splice donor site of the exon 17–intron 17 boundary. Family segregation analysis by Sanger sequencing confirmed that both siblings were homozygous for the variant, whereas both asymptomatic parents were heterozygous carriers. Although functional RNA studies were unavailable, two independent AI-based splicing tools provided concordant evidence of donor-site disruption: SpliceAI predicted a high-confidence donor-loss score (DS-DL = 0.98), while Pangolin predicted loss of the splice site at position −1 (score = 0.84), consistent with an in-frame exon-skipping event. The variant also had a high Combined Annotation Dependent Depletion (CADD) score (34), further supporting its predicted deleteriousness. These findings support its classification as Pathogenic (class 5) according to the American College of Medical Genetics and Genomics and Association for Molecular Pathology (ACMG/AMP) criteria (Table 2).
Outcome
Four patients, all carrying the recurrent RFXANK c.338-25_338del26 founder variant, underwent HLA-identical hematopoietic stem cell transplantation (HSCT) at a median age of 69 mo (range, 60–90). All received busulfan and fludarabine conditioning, with cyclosporine and methotrexate for graft-versus-host disease (GVHD) prophylaxis. All patients achieved full donor chimerism by 6 mo after HSCT, with robust immune reconstitution documented at 12 mo. P21 and P23 developed grade 1 acute GVHD within the first month after transplantation, and none developed chronic GVHD. Post-HSCT follow-up ranged from 18 to 56 mo (median, 43 mo). All four patients remained alive with good clinical status at last follow-up. Posttransplant infectious complications were infrequent, and no CMV reactivation was observed. P23 developed bronchopulmonary aspergillosis, while P29 experienced an episode of Haemophilus-associated pneumonia and molluscum contagiosum. The remaining two patients had no notable infectious complications during follow-up (Table 3).
Table 3.
HSCT characteristics and outcomes in four patients with MHC class II deficiency
| Patient | Age at HSCT (mo) | Donor type | Stem-cell source | Conditioning regimen | GVHD prophylaxis | Acute GVHD | Chronic GVHD | Post-transplant severe invasive infection | Donor chimerism at 6 mo | Immune reconstitution at 12 mo | Follow-up duration (mo) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P21 | 90 | HLA-identical donor | Peripheral blood stem cells | Busulfan + fludarabine | Cyclosporine + methotrexate | Grade 1 GVHD at day +14 | None | None | Full donor chimerism (100%) | Good immune reconstitution | 32 | Alive, good clinical status |
| P23 | 60 | HLA-identical donor | Peripheral blood stem cells | Busulfan + fludarabine | Cyclosporine + methotrexate | Grade 1 GVHD at day +18 | None | Bronchopulmonary aspergillosis | Full donor chimerism (100%) | Good immune reconstitution | 18 | Alive, good clinical status |
| P29 | 78 | HLA-identical donor | Peripheral blood stem cells | Busulfan + fludarabine | Cyclosporine + methotrexate | None | None | None | Full donor chimerism (100%) | Good immune reconstitution | 54 | Alive, good clinical status |
| P30 | 54 | HLA-identical donor | Peripheral blood stem cells | Busulfan + fludarabine | Cyclosporine + methotrexate | None | None | None | Full donor chimerism (100%) | Good immune reconstitution | 56 | Alive, good clinical status |
Among the 42 nontransplanted patients, 15 (35.7%) remain alive and continue to receive immunoglobulin replacement therapy and antibiotic and antifungal prophylaxis. Their median age at last follow-up was 84 mo (IQR, 60–168), ranging from 15 mo to 19 years. The remaining 27 patients died from infectious complications, often in the context of severe malnutrition, with a median age at death of 36 mo (IQR, 18–60) (Table 1 and Fig. 3 B). Given the small number of patients with RFXAP and CIITA variants, genotype-specific outcome comparisons were not feasible. Nevertheless, patients with RFXAP and CIITA variants had significantly earlier symptom onset and diagnosis than those with RFXANK variants (P = 0.022 and P = 0.002, respectively), and all had severe disease with early mortality (Table S3). In contrast, all patients with a milder phenotype and survival into adulthood had RFXANK deficiency caused by the recurrent founder variant.
Discussion
MHC class II deficiency is the most prevalent CID in Algeria and across the Maghreb, likely reflecting the combined effects of the recurrent RFXANK founder variant (c.338-25_338del26) and high consanguinity rates (10, 15, 20, 21). Nevertheless, the clinical and molecular spectrum of the disease in the region remains incompletely defined, with previous cohorts being relatively small and largely focused on the founder variant (11, 12). In this large Algerian cohort, systematic clinical, immunological, and genetic characterization further delineated the disease phenotype. While confirming the marked predominance of the founder RFXANK variant, we identified additional genetic and phenotypic heterogeneity, including a novel CIITA variant and an RFXAP mutation not previously reported in Algerian patients.
In our cohort, MHC class II deficiency presented early in infancy, with a median age at symptom onset of 4.5 mo, a median age at diagnosis of 17.5 mo, and a median diagnostic delay of 11 mo. Consistently, the median age at symptom onset was 6 mo in both Moroccan and Tunisian cohorts, whereas the median age at diagnosis was 19 and 24 mo, respectively (12, 13). Notably, a subset of patients exhibited a milder course, characterized by later symptom onset and diagnosis, with three patients surviving into adulthood without transplantation. This observation is consistent with reports from other Maghrebi cohorts and further underscores the marked phenotypic heterogeneity of MHC class II deficiency (12, 13). Across other Middle East and North Africa (MENA) cohorts, the median age at symptom onset was 4 mo in both Egyptian (22) and Turkish (23) cohorts and 5.5 mo in the Iranian cohort (24), whereas the median age at diagnosis was 21, 7, and 12 mo, respectively.
The clinical spectrum was dominated by recurrent respiratory infections, chronic diarrhea, and failure to thrive. Recurrent pneumonia occurred in 71.7% of patients, comparable with frequencies reported in Moroccan (74.1%), Tunisian (82.4%), and Turkish (82.9%) cohorts (12, 13, 23). Chronic diarrhea was a prominent feature, occurring in 80.4% of patients (37/46), compared with 76.5%, 74.3%, and 63% in the Tunisian, Turkish, and Moroccan cohorts, respectively (12, 13, 23). This high frequency highlights the potential value of persistent diarrhea as a clinical red flag for MHC class II deficiency, particularly in endemic settings such as Algeria. Opportunistic infections and complications following live-attenuated vaccines are well-recognized features of MHC class II deficiency (13, 22). No cases of BCG-itis or poliovirus vaccine–associated complications were documented in our cohort. However, mucocutaneous candidiasis was common, with oral candidiasis occurring in 54.3% of patients, comparable with rates reported in Tunisian (67.6%) and Moroccan (50%) cohorts (12, 13). In addition, Cryptosporidium spp. was identified in three patients with persistent diarrhea, consistent with findings from the Tunisian cohort and further supporting a role for this opportunistic parasite in the gastrointestinal phenotype of MHC class II deficiency.
Autoimmune manifestations were observed in 6 of 46 patients (13.0%), a lower frequency than that reported in Iranian (30%), Moroccan (20.4%), and Turkish (19%) cohorts (13, 23, 24). Nevertheless, autoimmunity remains a clinically relevant feature of MHC class II deficiency, with AIHA being the predominant manifestation, occurring in 6.5% of patients, a frequency comparable with that reported in the Moroccan cohort (5.6%) (13). The occurrence of autoimmunity despite profound impairment of HLA class II–dependent antigen presentation is noteworthy. Although such impairment would be expected to limit peripheral T cell activation and T–B cell cooperation, thereby constraining autoimmune responses, autoimmune manifestations nevertheless occur in a subset of patients. This apparent paradox underscores the complex contribution of MHC class II–dependent pathways to immune tolerance (25).
Immunologically, MHC class II deficiency was most often associated with CD4 lymphopenia, an inverted CD4/CD8 ratio, normal-to-increased CD8 T cell counts, and preserved B and NK cell compartments. That said, no single lymphocyte profile was pathognomonic of MHC class II deficiency, with profiles ranging from near-normal immunophenotypes (e.g., P6 and P26) to profound T cell lymphopenia approaching a SCID-like phenotype (e.g., P45 and P46). Importantly, 6 of 46 patients (13%) had normal CD4+ T cell counts, a proportion similar to that reported in the Moroccan cohort (13). Normal CD4+ T cell counts may reflect genuine preservation of the naive T cell compartment, as observed in P26, who was diagnosed through family screening before the onset of recurrent infections, whereas in most other cases, they were associated with expansion of memory CD4+ T cell subsets. Serum immunoglobulin profiles showed a similar degree of variability, with preserved IgG and/or IgM levels in more than half of patients, whereas IgA was markedly reduced in more than 70% of cases. Taken together, these findings highlight the broad immunophenotypic spectrum of MHC class II deficiency. The diagnosis should therefore be considered even in patients with relatively preserved lymphocyte counts when characteristic clinical manifestations, including protracted diarrhea, recurrent pneumonia, or oral candidiasis, are present. Assessment of HLA-DR expression should be incorporated into the initial immunological workup to minimize missed or delayed diagnoses, particularly in Algeria and the broader Maghreb, where this disorder remains prevalent. Early recognition is critical given the substantial morbidity associated with delayed diagnosis.
HLA-DR surface expression is central to the laboratory evaluation of MHC class II deficiency. This rapid and readily available assay is particularly valuable in resource-limited settings such as the Maghreb, where access to sequencing may be limited. Monocyte HLA-DR expression was absent or nearly absent in all patients, whereas B cell HLA-DR expression followed two distinct patterns. The predominant pattern was characterized by absent or nearly absent (≤2%) HLA-DR expression on both B cells and monocytes. The second was characterized by residual expression on B cells, which could involve a substantial proportion of cells despite markedly reduced MFI, at least 10-fold lower than that of healthy controls. B cell expression could also fluctuate, with transient increases during intercurrent infections. Similar findings were reported by Ouederni et al., who observed residual HLA-DR expression on B cells, but not monocytes, in a subset of patients with RFXANK deficiency, reaching 43% HLA-DR–positive B cells in one patient during a viral infection (10). This discordance supports cell type–specific differences in the regulation of HLA-DR expression between B cells and monocytes. A similar cell type–specific pattern was observed in RFX5-deficient mice, in which MHC class II expression was inducible in activated B cells but remained undetectable in macrophages, even after IFN-γ stimulation (26). Taken together, these findings underscore the importance of evaluating HLA-DR on both B cells and monocytes and of integrating percentage positivity with MFI measurements. Such a comprehensive approach enables accurate interpretation and minimizes the risk of misclassification.
Among the 35 patients who underwent genetic characterization, 30 (85.7%) carried the recurrent RFXANK c.338-25_338del26 mutation. The same founder variant was identified in 34 of 35 (97.1%) Moroccan patients and 25 of 34 (73.5%) Tunisian patients, further supporting a shared founder effect across Maghrebi populations (10, 11, 12, 13). The corresponding founder event was estimated to have occurred ∼2,250 years ago (95% confidence interval [CI], 1,700–3,025 years) (10). A distinct RFXANK founder variant was identified in Iran, where pathogenic RFXANK variants accounted for 72% of cases, including 6 of 18 patients carrying the homozygous c.162delG frameshift variant (23). This variant was traced to a distinct founder event estimated at ∼1,296 years ago (95% CI, 702–2,457 years) (24). In contrast, the molecular landscape was more heterogeneous in other MENA populations, with RFXANK, RFX5, CIITA, and RFXAP contributing variably to disease. In Turkish patients, these genes accounted for 39.1%, 34.8%, 17.4%, and 8.7% of cases, respectively, whereas in the Egyptian cohort, RFXANK, RFX5, and CIITA accounted for 50%, 37.5%, and 12.5%, respectively (22, 23). Collectively, these findings reveal substantial regional variation in the genetic architecture of MHC class II deficiency, with a founder-driven RFXANK pattern predominating in the Maghreb and greater molecular heterogeneity across other MENA populations (Fig. 4). Accordingly, in patients of Maghrebi ancestry with a compatible clinical and immunological phenotype, a stepwise genetic testing strategy may be appropriate. PCR-based screening for the recurrent RFXANK c.338-25_338del26 founder variant, followed by Sanger sequencing for confirmation, may provide a simple and cost-effective first-line approach. If the founder variant is not identified, broader molecular testing of other MHC class II regulatory genes using a targeted gene panel or whole-exome sequencing (WES) can be considered (27).
Figure 4.

Genetic landscape of MHC class II deficiency across the MENA region. Regional variation in the genetic architecture of MHC class II deficiency, characterized by a founder-driven RFXANK pattern in the Maghreb and greater molecular heterogeneity across other MENA populations (12, 13, 22, 23, 24).
Importantly, our study expands the molecular spectrum of MHC class II deficiency in Algeria beyond the recurrent RFXANK c.338-25_338del26 founder variant. We identified pathogenic variants in two additional MHC class II regulatory genes, RFXAP and CIITA, representing, to our knowledge, the first reported Algerian cases attributable to defects in genes other than RFXANK. We also identified a novel homozygous RFXANK variant (c.673insC), predicted to cause a frameshift and premature termination, consistent with a loss-of-function effect. The previously reported homozygous RFXAP c.368del variant was identified in two unrelated patients and is predicted to result in premature termination (p.Ser123ThrfsTer15) and loss of functional protein. A novel homozygous CIITA c.3233+1G>A variant was identified in two siblings, with segregation supporting a recessive mode of inheritance. Although functional RNA studies were unavailable, concordant in silico predictions from SpliceAI and Pangolin indicated disruption of the canonical splice donor site, presumably resulting in an in-frame exon-skipping event. Together with the high CADD score, these findings support a deleterious effect on CIITA splicing and consequent impairment of MHC class II expression.
Previous studies have linked RFXANK deficiency to later disease onset and a milder clinical course than defects in other MHC class II regulatory genes (23, 28). Consistent with these observations, patients with RFXAP or CIITA variants in our cohort had significantly earlier disease onset and diagnosis than those with RFXANK variants, whereas all patients with milder disease and delayed diagnosis carried the recurrent RFXANK variant. These findings suggest a potential genotype–phenotype relationship but should be interpreted cautiously given the small number of patients carrying non-RFXANK variants. Importantly, substantial clinical variability was observed even among patients carrying the same RFXANK c.338-25_338del26 founder variant, as noted above. This intragenotypic variability suggests that the clinical expression of MHC class II deficiency reflects the interplay between the causative variant and additional host and environmental factors, including genetic modifiers, host immune factors, and differences in infectious exposure and pathogen burden. Larger cohorts integrating comprehensive genetic and functional analyses will be essential to delineate the contribution of these factors to disease severity and clinical course.
Only four patients underwent HSCT, limiting the strength of conclusions regarding transplantation outcomes. Nevertheless, all four remained alive with good clinical status at last follow-up and achieved full donor chimerism with robust immune reconstitution by 1 year after HSCT. Over a median follow-up of 43 mo, no chronic GVHD or CMV reactivation was observed. Apart from P23, who developed bronchopulmonary aspergillosis, none of the transplanted patients experienced severe invasive infections or vaccine-related complications. These outcomes compare favorably with those reported in a Turkish cohort, where BCG-itis occurred in two of 10 transplanted patients and CMV viremia in seven, including five reactivations and two primary infections, with one patient developing CMV retinitis and permanent visual impairment (29). Despite the small number of transplanted patients, our findings indicate generally favorable post-HSCT outcomes in MHC class II deficiency.
Among the 42 patients who did not undergo HSCT, nearly two-thirds died at a median age of 3 years, predominantly from infectious complications, often in the context of severe malnutrition. These findings underscore the substantial mortality associated with MHC class II deficiency in the absence of definitive therapy. Despite this overall severe course, a subset of patients exhibited a milder phenotype, including three who survived into adulthood without HSCT; all carried the recurrent RFXANK c.338-25_338del26 founder variant. Similarly, survival into the second and third decades without HSCT has been reported in Tunisian and Moroccan patients carrying the same variant, further highlighting the marked clinical heterogeneity associated with the founder RFXANK variant (12, 13). Residual MHC class II expression does not appear to account for this heterogeneity, as only one of our three patients with long-term survival showed residual expression on B cells, consistent with observations from the Tunisian cohort (12).
In summary, MHC class II deficiency is the most frequently reported CID in the Maghreb, yet its clinical and immunologic spectrum remains incompletely defined. Our cohort of 46 patients provides a comprehensive clinical, immunologic, and molecular characterization, revealing substantial phenotypic heterogeneity, from severe early-onset disease to milder forms with survival into adulthood and from near-normal lymphocyte profiles to SCID-like T cell lymphopenia. Importantly, no single lymphocyte phenotype was pathognomonic of MHC class II deficiency. Thus, incorporating HLA-DR expression assessment into first-line immunologic investigations may facilitate earlier recognition and reduce missed or delayed diagnoses. Molecular analysis further expanded the genetic spectrum beyond the recurrent RFXANK founder variant, with additional RFXAP and CIITA variants identified in patients with earlier disease onset and a more severe clinical course. Larger, multicenter studies of genetically characterized cohorts across the Maghreb are needed to validate these observations and clarify the contribution of the underlying genetic defect to clinical severity.
Materials and methods
Study participants
46 Algerian patients with MHC class II deficiency, from 42 kindreds, were enrolled over an 8-year period (June 2018 to June 2026). All patients fulfilled the European Society for Immunodeficiencies criteria for MHC class II deficiency, which served as the inclusion criteria (www.esid.org). In 35 patients, genetic characterization was performed, and the underlying genetic defect was identified. Data were systematically collected for each patient using a standardized data form and entered into a computerized database. Collected information included demographic characteristics, family history, clinical data (age at symptom onset, age at diagnosis, infectious history, and features of immune dysregulation), as well as laboratory and imaging findings. The interval between symptom onset and diagnosis of MHC class II deficiency was defined as the diagnostic delay. The cohort included 29 patients previously captured in the Algerian IEI registry (15), and none belonged to the previously reported 11-patient Algerian MHC class II deficiency cohort (11). All participants provided informed consent. The study was approved by the Local Ethics Committee of Rouiba University Hospital (approval no.: CEH_R 002-2026) and conducted in accordance with the Declaration of Helsinki.
Serum immunoglobulin measurement
Serum immunoglobulin (IgG, IgM, and IgA) levels were measured by nephelometry using the BN ProSpec System (Siemens Healthineers).
T-B-NK enumeration
Basic immunophenotyping of circulating lymphocyte subsets, commonly referred to as T-B-NK enumeration, was performed in all patients using an eight-color FACSLyric cytometer (BD Biosciences). The assay utilized a six-color panel (i.e., CD3-FITC, CD16/56-PE, CD45-PerCP-Cy5.5, CD4-PE-Cy7, CD19-APC, and CD8-APC-Cy7) to define major lymphocyte populations: CD3 as a pan-T cell marker, CD4 for T helper cells, CD8 for cytotoxic T cells, CD19 for B cells, and CD56/CD16 for NK cells. Lymphocytes were identified and gated based on CD45 expression versus side scatter, and the relative frequencies of each subpopulation were determined.
Extended phenotyping of T and B cell subsets
Detailed analysis of naive and memory T cell subsets was performed in 29 patients using a six-color panel comprising CD3, CD4, CD8, CD45RA, CD45RO, and CCR7 (CD197), allowing identification of naive (CD45RA+CCR7+), memory (CD45RO+), and terminally differentiated effector memory CD45RA+ subsets within CD4+ and CD8+ T cells. Extended phenotyping of circulating B cells was performed in 14 patients. A multicolor panel, incorporating CD19, CD27, sIgD, CD24, CD38, and CD21 markers, was used to analyze different B cell subpopulations, including naive (CD27−sIgD+), switched memory (CD27+sIgD−), non-switched memory (CD27+sIgD+), transitional (CD38hiCD24hi), plasmablasts (CD38hiCD24−), and CD21lo B cells (CD38loCD21lo).
Analysis of surface HLA-DR expression by flow cytometry
Surface expression of HLA-DR on monocytes and B cells was assessed as previously described (30). Briefly, whole-blood samples were stained with CD14-FITC (clone M5E2; BD Biosciences), CD3-PerCP-Cy5.5 (clone SK7; BD Biosciences), CD20-APC (clone L27; BD Biosciences), and HLA-DR-PE (clone L243; BD Biosciences). Following erythrocyte lysis, cells were washed and analyzed by flow cytometry. The percentage of HLA-DR–positive B cells and monocytes and the corresponding MFI were determined and compared with healthy controls.
Genetic testing
To characterize the genetic basis of MHC class II deficiency, WES was performed on genomic DNA from 35 patients using the Illumina Exome Enrichment kit and the NextSeq 2000 platform, according to the manufacturer’s protocols. Sequencing was performed using 150-bp paired-end reads, and WES data were analyzed using Emedgene Analyze (Illumina). Variants were first filtered based on rarity in population databases, including gnomAD, and subsequently prioritized according to in silico pathogenicity predictions and relevance to genes involved in MHC class II expression. Candidate variants were then reviewed and classified according to the ACMG/AMP guidelines. Variants identified by WES were confirmed by Sanger sequencing, and segregation analysis was performed in available family members. For variants affecting canonical splice sites, in silico splicing predictions were performed using SpliceAI and Pangolin to assess their potential impact on pre-mRNA splicing. CADD scores were also considered as an additional measure of predicted variant deleteriousness.
Statistical analyses
Statistical analyses were performed with SPSS software, version 25.0 (IBM). Categorical variables were compared using the Chi-square test or Fisher’s exact test, as appropriate. Continuous variables were summarized as medians with interquartile ranges and compared using the Mann–Whitney U test. Statistical significance was set at a two-sided P value < 0.05.
Online supplemental material
Supplementary materials include Table S1, summarizing lymphocyte phenotypes, MHC class II expression, and serum immunoglobulin levels in patients with MHC class II deficiency; Table S2, showing HLA-DR expression on B cells and monocytes in P27, P42, and a healthy control; and Table S3, comparing age at symptom onset and age at diagnosis in patients with RFXANK deficiency and those with RFXAP or CIITA deficiency.
Supplementary Material
shows lymphocyte phenotype, MHC class II expression, and serum immunoglobulins in patients with MHC class II deficiency.
shows HLA-DR expression on B cells and monocytes in P27, P42, and a healthy control.
shows a comparison of age at symptom onset and age at diagnosis in patients with RFXANK deficiency versus those with RFXAP or CIITA deficiency.
Acknowledgments
We express our deepest gratitude to the patients and their families to whom this work is dedicated. We gratefully acknowledge the “Établissement Publique Hospitalier de Rouiba” for its institutional support in diagnostic investigations and immunophenotypic characterization.
This research was supported in part by the Intramural Research Program of the National Institutes of Health (NIH). The contributions of the NIH authors are considered Works of the United States Government. The findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S. Department of Health and Human Services.
Author contributions: Azzeddine Tahiat: conceptualization, data curation, formal analysis, investigation, methodology, resources, software, supervision, validation, visualization, and writing—original draft, review, and editing. Lorenzo Cuollo: data curation, formal analysis, investigation, and writing—review and editing. Sofija Buta Panov: investigation. Saliha Hakem: data curation, formal analysis, investigation, resources, and writing—review and editing. Souad Touri: data curation, formal analysis, investigation, validation, and writing—review and editing. Amina Saad-Djaballah: conceptualization, data curation, and investigation. Chafa Bendahmane: data curation, formal analysis, and writing—review and editing. Abdelbassat Ketfi: conceptualization, methodology, supervision, validation, visualization, and writing—original draft, review, and editing. Abdelghani Yagoubi: investigation, resources, and writing—review and editing. Reda Belbouab: resources. Leila Smati: data curation and writing—original draft, review, and editing. Rachida Boukari: data curation, resources, supervision, and visualization. Sergio D. Rosenzweig: formal analysis, investigation, and writing—review and editing. Luigi D. Notarangelo: data curation, funding acquisition, investigation, and writing—review and editing. Malek Benakli: investigation, resources. Dusan Bogunovic: methodology, resources, and writing—review and editing. Kamel Djenouhat: conceptualization, formal analysis, investigation, supervision, validation, visualization, and writing—review and editing.
Data availability
Data are available from the corresponding authors upon reasonable request, subject to applicable national regulations and institutional requirements governing the sharing of patient-level data.
References
- 1. Hanna, S., and Etzioni A.. 2014. MHC class I and II deficiencies. J. Allergy Clin. Immunol. 134:269–275. 10.1016/j.jaci.2014.06.001 [DOI] [PubMed] [Google Scholar]
- 2. Griscelli, C., Lisowska-Grospierre B., Le Deist F., Durandy A., Marcadet A., Fischer A., de Preval C., and Mach B.. 1989. Combined immunodeficiency with abnormal expression of MHC class II genes. Clin. Immunol. Immunopathol. 50:S140–S148. 10.1016/0090-1229(89)90121-9 [DOI] [PubMed] [Google Scholar]
- 3. Mach, B., Steimle V., Martinez-Soria E., and Reith W.. 1996. Regulation of MHC class II genes: Lessons from a disease. Annu. Rev. Immunol. 14:301–331. 10.1146/annurev.immunol.14.1.301 [DOI] [PubMed] [Google Scholar]
- 4. Villard, J., Masternak K., Lisowska-Grospierre B., Fischer A., and Reith W.. 2001. MHC class II deficiency: A disease of gene regulation. Medicine (Baltimore). 80:405–418. 10.1097/00005792-200111000-00006 [DOI] [PubMed] [Google Scholar]
- 5. Steimle, V., Otten L.A., Zufferey M., and Mach B.. 1993. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell. 75:135–146. 10.1016/s0092-8674(05)80090-x [DOI] [PubMed] [Google Scholar]
- 6. Masternak, K., Barras E., Zufferey M., Conrad B., Corthals G., Aebersold R., Sanchez J.C., Hochstrasser D.F., Mach B., and Reith W.. 1998. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat. Genet. 20:273–277. 10.1038/3081 [DOI] [PubMed] [Google Scholar]
- 7. Steimle, V., Durand B., Barras E., Zufferey M., Hadam M.R., Mach B., and Reith W.. 1995. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev. 9:1021–1032. 10.1101/gad.9.9.1021 [DOI] [PubMed] [Google Scholar]
- 8. Durand, B., Sperisen P., Emery P., Barras E., Zufferey M., Mach B., and Reith W.. 1997. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. EMBO J. 16:1045–1055. 10.1093/emboj/16.5.1045 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Masternak, K., Muhlethaler-Mottet A., Villard J., Zufferey M., Steimle V., and Reith W.. 2000. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 14:1156–1166. 10.1101/gad.14.9.1156 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Ouederni, M., Vincent Q.B., Frange P., Touzot F., Scerra S., Bejaoui M., Bousfiha A., Levy Y., Lisowska-Grospierre B., Canioni D., et al. 2011. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: A survey of 35 patients. Blood. 118:5108–5118. 10.1182/blood-2011-05-352716 [DOI] [PubMed] [Google Scholar]
- 11. Djidjik, R., Messaoudani N., Tahiat A., Meddour Y., Chaib S., Atek A., Khiari M.E., Benhalla N.K., Smati L., Bensenouci A., et al. 2012. Clinical, immunological and genetic features in eleven Algerian patients with major histocompatibility complex class II expression deficiency. Allergy Asthma Clin. Immunol. 8:14. 10.1186/1710-1492-8-14 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Ben-Mustapha, I., Ben-Farhat K., Guirat-Dhouib N., Dhemaied E., Largueche B., Ben-Ali M., Chemli J., Bouguila J., Ben-Mansour L., Mellouli F., et al. 2013. Clinical, immunological and genetic findings of a large Tunisian series of major histocompatibility complex class II deficiency patients. J. Clin. Immunol. 33:865–870. 10.1007/s10875-013-9863-8 [DOI] [PubMed] [Google Scholar]
- 13. Kattra, A.B., Ailal F., Benhsaien I., Rada N., Admou B., Hazime R., Benajiba N., El Hafidi N., Hbibi M., Hida M., et al. 2026. Major histocompatibility complex class II deficiency in Morocco: A 26-year retrospective cohort study. Front. Immunol. 17:1831840. 10.3389/fimmu.2026.1831840 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Wiszniewski, W., Fondaneche M.C., Le Deist F., Kanariou M., Selz F., Brousse N., Steimle V., Barbieri G., Alcaide-Loridan C., Charron D., et al. 2001. Mutation in the class II trans-activator leading to a mild immunodeficiency. J. Immunol. 167:1787–1794. 10.4049/jimmunol.167.3.1787 [DOI] [PubMed] [Google Scholar]
- 15. Yagoubi, A., Tahiat A., Touri N.S., Ladj M.S., Drali O., Belaid B., Mohand-Oussaid A., Dehimi A., Belbouab R., Ferhani Y., et al. 2022. Algerian registry for inborn errors of immunity in children: Report of 887 children (1985-2021). J. Clin. Immunol. 42:1660–1671. 10.1007/s10875-022-01330-5 [DOI] [PubMed] [Google Scholar]
- 16. Morbach, H., Eichhorn E.M., Liese J.G., and Girschick H.J.. 2010. Reference values for B cell subpopulations from infancy to adulthood. Clin. Exp. Immunol. 162:271–279. 10.1111/j.1365-2249.2010.04206.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Shearer, W.T., Rosenblatt H.M., Gelman R.S., Oyomopito R., Plaeger S., Stiehm E.R., Wara D.W., Douglas S.D., Luzuriaga K., McFarland E.J., et al. 2003. Lymphocyte subsets in healthy children from birth through 18 years of age: The Pediatric AIDS clinical trials group P1009 study. J. Allergy Clin. Immunol. 112:973–980. 10.1016/j.jaci.2003.07.003 [DOI] [PubMed] [Google Scholar]
- 18. Nekrep, N., Jabrane-Ferrat N., and Peterlin B.M.. 2000. Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex. Mol. Cell. Biol. 20:4455–4461. 10.1128/mcb.20.12.4455-4461.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Schmetterer, K.G., Seidel M.G., Körmöczi U., Rottal A., Schwarz K., Matthes-Martin S., Steinberger P., and Pickl W.F.. 2010. Two newly diagnosed HLA class II-deficient patients identified by rapid vector-based complementation analysis reveal discoordinate invariant chain expression levels. Int. Arch. Allergy Immunol. 152:390–400. 10.1159/000288292 [DOI] [PubMed] [Google Scholar]
- 20. Mellouli, F., Mustapha I.B., Khaled M.B., Besbes H., Ouederni M., Mekki N., Ali M.B., Larguèche B., Hachicha M., Sfar T., et al. 2015. Report of the Tunisian registry of primary immunodeficiencies: 25-years of experience (1988-2012). J. Clin. Immunol. 35:745–753. 10.1007/s10875-015-0206-9 [DOI] [PubMed] [Google Scholar]
- 21. Bousfiha, A.A., Jeddane L., El Hafidi N., Benajiba N., Rada N., El Bakkouri J., Kili A., Benmiloud S., Benhsaien I., Faiz I., et al. 2014. First report on the Moroccan registry of primary immunodeficiencies: 15 years of experience (1998-2012). J. Clin. Immunol. 34:459–468. 10.1007/s10875-014-0005-8 [DOI] [PubMed] [Google Scholar]
- 22. El Hawary, R.E., Mauracher A.A., Meshaal S.S., Eldash A., Abd Elaziz D.S., Alkady R., Lotfy S., Opitz L., Galal N.M., Boutros J.A., et al. 2019. MHC-II deficiency among Egyptians: Novel mutations and unique phenotypes. J. Allergy Clin. Immunol. Pract. 7:856–863. 10.1016/j.jaip.2018.07.046 [DOI] [PubMed] [Google Scholar]
- 23. Gulec Koksal, Z., Eltan S.B., Topyildiz E., Sezer A., Keles S., Celik F.C., Kont A.O., Karaaslan B.G., Sefer A.P., Karali Z., et al. 2024. MHC class II deficiency: Clinical, immunological, and genetic insights in a large multicenter cohort. J. Allergy Clin. Immunol. Pract. 12:2490–2502.e6. 10.1016/j.jaip.2024.06.046 [DOI] [PubMed] [Google Scholar]
- 24. Mousavi Khorshidi, M.S., Seeleuthner Y., Chavoshzadeh Z., Behfar M., Hamidieh A.A., Alimadadi H., Sherkat R., Momen T., Behniafard N., Eskandarzadeh S., et al. 2023. Clinical, immunological, and genetic findings in Iranian patients with MHC-II deficiency: Confirmation of c.162delG RFXANK founder mutation in the Iranian population. J. Clin. Immunol. 43:1941–1952. 10.1007/s10875-023-01562-z [DOI] [PubMed] [Google Scholar]
- 25. Tahiat, A., Touri S., Saad-Djaballah A., Hakem S., Fernini F., Aggoune S., Belhadj H., Bendahmane C., Mokrane L., Bencharif Madani T., et al. 2025. Mapping the landscape of autoimmunity and autoinflammation in inborn errors of immunity: Broad distribution with distinct clustering patterns. Front. Immunol. 16:1725282. 10.3389/fimmu.2025.1725282 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Clausen, B.E., Waldburger J.-M., Schwenk F., Barras E., Mach B., Rajewsky K., Förster I., and Reith W.. 1998. Residual MHC class II expression on mature dendritic cells and activated B cells in RFX5-deficient mice. Immunity. 8:143–155. 10.1016/s1074-7613(00)80467-7 [DOI] [PubMed] [Google Scholar]
- 27. Baris, S., Abolhassani H., Massaad M.J., Al-Nesf M., Chavoshzadeh Z., Keles S., Reisli I., Tahiat A., Shendi H.M., Elaziz D.A., et al. 2023. The Middle East and North Africa diagnosis and management guidelines for inborn errors of immunity. J. Allergy Clin. Immunol. Pract. 11:158–180.e11. 10.1016/j.jaip.2022.10.003 [DOI] [PubMed] [Google Scholar]
- 28. Prod’homme, T., Dekel B., Barbieri G., Lisowska-Grospierre B., Katz R., Charron D., Alcaide-Loridan C., and Pollack S.. 2003. Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course. Immunogenetics. 55:530–539. 10.1007/s00251-003-0609-2 [DOI] [PubMed] [Google Scholar]
- 29. Haskologlu, S., Aytekin C., Islamoglu C., Kostel Bal S., Baskın K., Erman B., Kendirli T., Ceylaner S., Dogu F., and Ikinciogullari A.. 2026. Clinical, immunological, treatment characteristics, and outcomes in 22 patients with major histocompatibility complex class II deficiency. Front. Immunol. 17:1811502. 10.3389/fimmu.2026.1811502 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Tahiat, A., Belbouab R., Yagoubi A., Hakem S., Fernini F., Keddari M., Belhadj H., Touri S., Aggoune S., Stoddard J., et al. 2024. Flow cytometry-based diagnostic approach for inborn errors of immunity: Experience from Algeria. Front. Immunol. 15:1402038. 10.3389/fimmu.2024.1402038 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
shows lymphocyte phenotype, MHC class II expression, and serum immunoglobulins in patients with MHC class II deficiency.
shows HLA-DR expression on B cells and monocytes in P27, P42, and a healthy control.
shows a comparison of age at symptom onset and age at diagnosis in patients with RFXANK deficiency versus those with RFXAP or CIITA deficiency.
Data Availability Statement
Data are available from the corresponding authors upon reasonable request, subject to applicable national regulations and institutional requirements governing the sharing of patient-level data.
